ArticleVeterinary and comparative oncology2026
LOX and LOXL2 Expression in Canine Mammary Carcinomas.
Article in Veterinary and comparative oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LOX and LOXL2 Expression in Canine Mammary Carcinomas.Veterinary and comparative oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mammary tumours account for approximately 50% of the neoplasms in female dogs. Even conventionally accepted prognostic indicators often fail to reliably predict the clinical behaviour of these tumours, underscoring the need for more effective prognostic markers. Proteins of the LOX family are associated with tumour invasion and metastasis in several types of tumours. The purpose of this study was to characterise the immunohistochemical expression of LOX and LOXL2 in canine mammary carcinomas and to investigate their prognostic significance. Samples of mammary carcinomas from 80 female dogs with a minimum post-surgical follow-up of 180 days were analysed. Tumour samples were submitted to immunohistochemistry to detect LOX and LOXL2. Immunolabelling was evaluated based on scores for staining intensity and percentage of positive cells, and a combined score was used to classify each protein as having either 'low-' or 'high-expression'. The results were compared with histological types, mortality due to the disease and post-surgical survival. We found that negativity for LOXL2 expression was an indicator of higher risk of death due to the disease. Our results suggest that lysyl oxidases such as LOXL2 are potential prognostic markers in mammary carcinomas of dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.